Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
Takezako N, Shibayama H, Handa H, Hagiwara S, Ozaki S, Suzuki K, Kosugi H, Ri M, Sugiura I, Choi I, Miyamoto T, Iida S. Takezako N, et al. Among authors: kosugi h. Int J Hematol. 2021 Feb;113(2):219-230. doi: 10.1007/s12185-020-03013-6. Epub 2020 Oct 10. Int J Hematol. 2021. PMID: 33037990 Free PMC article.
Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).
Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Murakami H, et al. Among authors: kosugi h. Int J Hematol. 2019 Apr;109(4):409-417. doi: 10.1007/s12185-019-02607-z. Epub 2019 Jan 31. Int J Hematol. 2019. PMID: 30701467 Clinical Trial.
Correction to: Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).
Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Murakami H, et al. Among authors: kosugi h. Int J Hematol. 2019 Jul;110(1):125-126. doi: 10.1007/s12185-019-02663-5. Int J Hematol. 2019. PMID: 31119612
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.
Suzuki K, Doki N, Meguro K, Sunami K, Kosugi H, Sasaki O, Takagi T, Murakami H, Shimizu K. Suzuki K, et al. Among authors: kosugi h. Int J Hematol. 2019 Oct;110(4):447-457. doi: 10.1007/s12185-019-02700-3. Epub 2019 Jul 19. Int J Hematol. 2019. PMID: 31325152 Clinical Trial.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Ishida T, et al. Among authors: kosugi h. Ann Hematol. 2020 May;99(5):1063-1072. doi: 10.1007/s00277-020-03988-6. Epub 2020 Apr 4. Ann Hematol. 2020. PMID: 32248251 Clinical Trial.
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG. Kim K, et al. Among authors: kosugi h. Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723430 Free article.
114 results